May 23, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

CML Lung Cancer

» Advanced search

Paper of the Month - September, 2011

Please login to access this article in full. Click here to register for free now!

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


0 rating

Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer.

Schuchert MJ, Schumacher L, Kilic A et al.

In the current study, we analyze the impact of pathologic variables (angiolymphatic invasion, visceral pleural invasion, and tumor inflammation) upon survival outcomes after segmentectomy or lobectomy for stage I non-small cell lung cancer.

Please login or register to continue reading this article

View Archive »


Computed tomography appearance of early radiation injury to the lung: correlation with clinical and dosimetric factors. - March, 2012
Randomized Phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small cell lung cancer. - February, 2012
Survival after resection of synchronous non-small cell lung cancer. - January, 2012
Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. - September, 2011
Assessment of lung-cancer mortality reduction from CT screening. - August, 2011
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. - July, 2011
Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation. - June, 2011
Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. - May, 2011
Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. - April, 2011
High rates of tumour growth and disease progression detected on serial pre-treatment fluorodeoxyglucose-positron emission tomography/CT scans in radical radiotherapy candidates with non small cell lung cancer. - March, 2011
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised Phase III trial (AVAIL). - February, 2011
Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, Phase III trial. - January, 2011
Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? - October, 2011
Impact of neoadjuvant chemo-radiotherapy followed by surgical resection on node-negative T3 and T4 non-small cell lung cancer. - November, 2011
Randomized Phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. - December, 2011
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. - December, 2010
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. - November, 2010
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. - October, 2010
A randomized, Phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. - September, 2010
Stereotactic radiosurgery for the treatment of lung neoplasm: experience in 100 consecutive patients. - August, 2010
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase 3 study. - July, 2010
Outcome in a prospective Phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. - June, 2010
Preoperative staging of lung cancer with combined PET-CT. - May, 2010
Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. - April, 2010
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. - March, 2010
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. - February, 2010
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a Phase III randomised controlled trial. - January, 2010
Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. - December, 2009
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. - November, 2009
Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy. - October, 2009
Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. - September, 2009
Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. - August, 2009
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, Phase III study. - July, 2009
Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: the benefit is worth the risk. - June, 2009
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. - May, 2009
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized Phase III trial. - April, 2009
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. - March, 2009
A Phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. - February, 2009
Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients. - January, 2009

READER POLL

When treating advanced, partially resectable large cell neuroendocrine carcinomas of the lung, would you initially treat with:

Surgery?
Platinum-based Chemotherapy?
Radiotherapy?
Other Chemotherapy?
Combination Chemo-radiotherpy?

WEB LINKS

Original article

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 23, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

CML Lung Cancer » Advanced search